Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
987.6 USD | +0.72% | +0.61% | +12.52% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 29.08 times its estimated earnings per share for the ongoing year.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+11.65% | 106B | B+ | ||
+10.79% | 116B | B+ | ||
-6.20% | 23.89B | B+ | ||
-2.33% | 21.58B | B | ||
-6.03% | 18.96B | A- | ||
-13.41% | 16.33B | B | ||
-40.50% | 16.96B | A- | ||
+6.64% | 14.14B | C+ | ||
+31.84% | 12.02B | C+ | ||
-34.35% | 7.2B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- REGN Stock
- Ratings Regeneron Pharmaceuticals, Inc.